Tel Aviv University, Israel
Professor Emerita Illana Gozes, BSc, Tel Aviv University, Direct PhD, Weizmann Institute of Science (Best PhD Student Landau Prize), Israel, postdoc. MIT (Weizmann Fellowship) and Salk Institute, USA, Senior Scientist/Associate Professor, Weizmann Institute, Fogarty-Scholar-in-Residence, NIH, USA, currently, Professor for Clinical Biochemistry at Tel Aviv University (mentoring numerous students). She published >330 papers in neuroscience (h-index 76, >25,500 citations, https://scholar.google.co.il/citations?user=B1sLPv8AAAAJ&hl=en&oi=ao). Prof. Gozes is the inventor of many patents including CP201 (NAP, davunetide), a clinical drug candidate targeted at the rare disease indication, the ADNP syndrome (founded Allon Therapeutics and currently Chief Scientific Officer at Coronis Neurosciences). Professor Gozes discovered ADNP, an essential protein for brain formation implicated in autism, schizophrenia, Alzheimer’s disease and cancer. CP201 is a snippet of ADNP, enhancing ADNP’s protective activity. Prof. Gozes won many awards of excellence (including Tel Aviv University’s Vice President Award, Olson Prize, Julodan Prize, Teva Prize, Neufeld Award, Hanse-Wissenschaftskolleg (HWK) fellowship, Humboldt Award, Landau Prize for Life Achievements, 2013). Importantly, she is the Champion of Hope – Science International -2016, Global Genes. She is also the Ex-President of the Israel Society for Neuroscience, served on the Governing Committee and the Board of Governors of Tel Aviv University. Prof. Gozes is currently directing the Israeli Brain Bee Competition, serving as the Secretary of the European Society for Neurochemistry, a member of the Israeli Ministry of Education, Council of Higher Education and is the Editor-in-Chief of the Journal of Molecular Neuroscience (Springer-Nature Press).